Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity

Clinical and Experimental Rheumatology

Volumn 32, Issue 3, 2014, Pages 390-394

  Van Herwaarden, Noortje ^a   Herfkens Hol, Susan ^a   van der Maas, Aatke ^a   van den Bemt, Bart J F ^b   van Vollenhoven, Ronald F ^c   Bijlsma, Johannes W J ^d   den Broeder, Alfons A ^a  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b Department of Pharmacy Sint Maartenskliniek ^*  (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Dose response relationship; Rheumatoid arthritis; Tocilizumab

Indexed keywords

TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84901823265     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. KREMER JM, BLANCO R, BRZOSKO M et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
2. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
3. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
4. MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
5. NISHIMOTO N, HASHIMOTO J, MIYASAKA N et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
6. NISHIMOTO N, MIYASAKA N, YAMAMOTO K et al.: Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-9.
7. EuropeEan MeEdicineEs AageEncy: RoActemra; product information (last updated 31-01-2013) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000955/WC500054890.pdf. 2013.
8. Uu.Ss.Aa Food and Ddrug AadmMinistration: Highlights of prescribing information. 2013.
9. SCHOELS MM, van deer HEIJDE D, BREEDVELD FC et al.: Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72: 583-9.
10. CAMPBELL L, CHEN C, BHAGAT SS, PARKER RA, ÖSTÖR AJK: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011; 50: 552-62.
11. van deEr MAAS A, KIEVIT W, van deen BEMT BJ, van deEn HOOGEN FHJ, van RIEL PL, deEn BROEDER AA: Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012; 71: 1849-54.
12. SMOLEN JS, NASH P, DUREZ P et al.: Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a radnomised controlled trial. Lancet 2013; 381: 918-29.
13. ALLAART CF, LEMS WF, HUIZINGA TW: The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S14-S18.
14. TANAKA Y, HIRATA S, SALEEM B, EMERY P: Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S22-S27.
15. NISHIMOTO N AMANO K, HIRABAYASHI Y et al.: Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM STUDY). Mod Rheumatol 2014; 24: 17-25.
16. SMOLEN JS, SCHOELS MM, NISHIMOTO N et al.: Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013; 72: 482-92.
17. van VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG L: Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.